Yogvahi Action Of Rasasindoor With Aqueous Extract Of Eclipta Alba In Essential Hypertension: A Clinical Research Study

Abstract

Background Hypertension is a major global health concern and a leading risk factor for cardiovascular morbidity and mortality. In Ayurveda, it can be correlated to Vyanabala Vaishamya involving Vata predominance. Conventional anti-hypertensives often require lifelong use, prompting interest in safe, cost-effective alternatives. Bhringraj (Eclipta alba) has documented antihypertensive activity, while Rasasindoor is described as Yogvahi, enhancing the potency and bioavailability of co-administered drugs. This study was undertaken to evaluate the Yogvahi action of Rasasindoor in combination with Eclipta alba in Essential Hypertension.

Aim Of Study - To evaluate the Yogvahi action of Rasasindoor with aqueous extract of Eclipta alba upto stage 1 in management of Essential Hypertension. 

Objectives of Study-Primary: To evaluate the Yogvahi action of Rasasindoor with aqueous extract of Eclipta alba   in management of upto Essential Hypertension

Secondary:  to evaluate the safety of Rasasindoor with aqueous extract of Eclipta alba   in management of Essential Hypertension.

 Materials and Methods A randomized, open-label, comparative, interventional clinical trial was conducted on 100 patients of Essential Hypertension (as per JNC-7 criteria). Patients were randomly allocated into two groups: Group A received aqueous extract of Eclipta alba (500 mg), while Group B received Rasasindoor (62 mg) along with Eclipta alba (500 mg), twice daily for 30 days. Assessments were made at baseline, day 10, day 20, day 30, and follow-up on day 45 and 60. Objective parameters included systolic and diastolic blood pressure, mean arterial pressure (MAP), and pulse rate. Subjective parameters included Shirshoola, Bhrama, Klama, Hrutspandana, Swedadhikya, and Anidra. Safety was assessed through hematological, biochemical, and urinary investigations.

Results Both groups demonstrated significant reductions in blood pressure and symptomatic relief. Group B showed superior improvement with statistically significant intergroup differences in MAP and subjective symptoms like palpitation and insomnia (p < 0.05). Laboratory parameters remained within normal limits, indicating safety. Only one patient in Group B reported mild itching, which subsided without intervention.

Conclusion The study establishes the Yogvahi action of Rasasindoor in potentiating the antihypertensive effect of Eclipta alba. Combination therapy proved more effective than monotherapy, with favorable safety and tolerability. This integrative approach highlights the potential of Ayurvedic herbo-mineral formulations as supportive therapy in Essential Hypertension